Stocks of Coivid Vaccine Biotech Forms Start The Week With Mix Reaction

Nearly all the companies in the S&P 500 have now released their results for the third quarter, with positive surprises in terms of earnings for 84 percent of them. Ultimately, the earnings of the S&P 500 decreased by 6.3 percent in the third quarter relative to the same time in 2019, while analysts predicted a 21 percent decline at the end of September. The biggest declines were suffered in detail by three sectors: electricity, air transport and hotels/restaurants, both of which were plagued by the coronavirus crisis. Except these industries, profits were up 4.3% year-on-year, driven primarily by the healthcare sector (up 13%), as well as internet services, software, biotechnology, but also the automotive industry.

On Monday, stocks of biotech firms especially involved in coronavirus vaccines traded in distributed order, including Astrazeneca Plc (AZN) down -1% on Wall Street, Pfizer Inc (PFE) lost -0.5%, BioNTech SE (BNTX) jumped up 2.3% on Wall Street, Moderna Inc (MRNA) surged 3.5% and Curevac N.V. Inc (CVAC) gained 6.7%.

The New Jersey laboratory, Merck & Co., Inc. (MRK) was down -0.2 percent at first session of the week as it has confirmed the $425 million acquisition of OncoImmune, which produces a medication that can alleviate symptoms of Covid and minimize deaths in patients with serious types.

A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .


Regeneron Pharmaceuticals Inc. (REGN) started the week with a rise of 0.97% on Monday. Emergency use authorization has been issued by the FDA to treat Covid-19 with a combination of antibodies developed by the community. During his hospitalization following coronavirus infection in October, President Donald Trump was given the treatment. For mild to moderate cases in adults following good results, the use of the medication was approved. In early November, the FDA had already approved the treatment of Eli Lilly for newly infected patients at risk of developing a serious form of the disease.

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

Recent Articles

Is Micron Technology (MU) Better Pick Right Now?

A trend has been developing since October 2020 for Micron Technology Inc. (NASDAQ: MU). Looking back at the past, we will examine various forward...

Aurora Cannabis’ (ACB) Prospects In The Slow Cannabis Market

The Democratic win in the latest US elections and industry surveys have substantially resurrected the cannabis market, as a result of which shares of...

Is IMAX Corporation Looking Forward To A Good Year?

The movie theatre operator IMAX Company (IMAX) may be one of the winners of the delayed market for large-screen movie premieres. The recent announcement...

Shares of DermTech (DMTK) Risen 186% Over A Month

After announcing that its test had earned insurance coverage, the shares of biotech firm DermTech, Inc. (DMTK) started rising last month. The rally is...

Sales at KB Home (NYSE: KBH) Are Down, But Orders Are Up

Construction company KB Home (NYSE: KBH) recently released its results for the fourth quarter of 2020. The company's revenue and profits declined on a...

Related Stories

Leave A Reply

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

We do not sell or share your information with anyone.